查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1609164

神經科學市場：按類型、最終用戶分類 - 2025-2030 年全球預測

Neuroscience Market by Type (Diagnostic Solution, Drug Therapy, Non-drug Therapy), End-User (Diagnostic Laboratories, Hospitals, Research & Academic Institutes) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年神經科學市場規模為137.7億美元，預計2024年將達到151.1億美元，複合年成長率為10.34%，2030年將達274.2億美元。

神經科學作為市場研究領域的範圍涵蓋生物和認知科學的研究和應用，以了解和增強人腦功能。該領域的需求源於對治療神經系統疾病、心理健康挑戰和退化性疾病的解決方案的需求不斷成長。應用範圍涵蓋製藥、生物技術、認知神經科學和神經技術，最終用途領域包括醫療、教育和國防。市場成長受到腦部影像技術進步、神經學研究資金增加以及心理健康意識增強等因素的影響。人工智慧和機器學習技術的湧入為精神衛生保健領域的個人化治療計劃和預測分析等創新提供了重大機會。此外，由於 COVID-19 大流行，遠端醫療服務的擴展加速了神經科學主導的應用程式在遠端醫療環境中的整合。然而，挑戰依然存在，包括高昂的研發成本、監管障礙以及圍繞神經技術進步的倫理考量。此外，市場細分，少數強勢參與企業和大量利基開發商增加了競爭壓力。創新的成熟領域包括開發非侵入性神經刺激技術、增強腦機介面技術以及探索迷幻物質的治療潛力和神經效應。透過與大學和研究機構的合作、促進跨學科研究以及優先採用以患者為中心的產品開發方法，進一步促進業務成長。市場本質上是動態且快速發展的，要求企業對新趨勢和監管變化保持警惕。因此，神經科學市場的本質是具有很高的創新潛力，但也受到收益和道德部署方面的挑戰的影響，需要將研究重點和市場敏捷性進行策略性結合。

主要市場統計
基準年[2023] 137.7億美元
預計年份 [2024] 151.1億美元
預測年份 [2030] 274.2億美元
複合年成長率（%） 10.34%

市場動態：揭示快速發展的神經科學市場的關鍵市場洞察

供需的動態交互作用正在改變神經科學市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 全球神經系統疾病盛行率不斷上升
    • 神經系統疾病藥物發現和藥物開發的增加
    • 擴大利用神經科學來增強大腦健康和認知功能
  • 市場限制因素
    • 與神經科學研究相關的高成本
  • 市場機會
    • 擴大神經科學在個人化醫療開發的應用
    • 神經科學研究的有利資助狀況
  • 市場問題
    • 使用神經技術的功能限制

波特五力：駕馭神經科學市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解神經科學市場的外部影響

外部宏觀環境因素在塑造神經科學市場的績效動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析：了解神經科學市場的競爭格局

神經科學市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣：神經科學市場供應商的績效評估

FPNV 定位矩陣是評估神經科學市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：規劃神經科學市場的成功之路

神經科學市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1. 市場滲透率：詳細檢視當前市場環境，主要企業的廣泛資料，評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、主要產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 世界各地神經系統疾病的發生率正在增加
      • 增加神經系統疾病新藥的發現與開發
      • 更多地利用神經科學來增強大腦健康和認知功能
    • 抑制因素
      • 與神經科學研究相關的高成本
    • 機會
      • 神經科學在個人化醫療發展的新用途
      • 神經科學研究的有利資金籌措環境
    • 任務
      • 神經技術使用的功能限制
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章神經科學市場：依類型

  • 介紹
  • 診斷解決方案
    • 分子
      • 免疫檢測
      • 裝置
      • 套件和用品
      • 液相層析法
      • PCR
      • 定序
      • 軟體
    • 非分子
      • 腦幹聽覺誘發電位
      • 腦電圖測試
      • 影像
  • 藥物治療
    • 神經系統疾病
      • 阿茲海默症
      • 癲癇
      • 亨丁頓舞蹈症
      • 多發性硬化症
      • 帕金森氏症
      • 血管失智症
    • 神經精神疾病
      • 焦慮症
      • 注意力缺陷
      • 自閉症頻譜
      • 失眠
      • 情緒障礙
      • 藥物濫用
  • 非藥物治療
    • 行為療法
      • 動物干預
      • 在家工作
      • 住院病人
      • 門診病人
    • 數位醫療服務

第 7 章 神經科學市場：依最終使用者分類

  • 介紹
  • 診斷實驗室
  • 醫院
  • 研究/學術機構

第8章美洲神經科學市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太神經科學市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章歐洲、中東和非洲的神經科學市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Agilent Technologies, Inc.
  • Bayer AG
  • Bio-Rad Laboratories, Inc.
  • Brain Products GmbH
  • Compumedics Limited
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Gilson, Inc.
  • GL Sciences Inc.
  • Hitachi, Ltd.
  • Illumina, Inc.
  • JASCO Corporation
  • Merck KGaA
  • Metrohm AG
  • Natus Medical Incorporated
  • Novasep Holding SAS
  • PerkinElmer Inc.
  • Pfizer Inc.
  • Promega Corporation
  • QIAGEN GmbH
  • Restek Corporation
  • Shimadzu Corporation
  • Siemens AG
  • Thermo Fisher Scientific Inc.
  • Waters Corporation
  • YMC Co., Ltd.
Product Code: MRR-C002B1C9955F

The Neuroscience Market was valued at USD 13.77 billion in 2023, expected to reach USD 15.11 billion in 2024, and is projected to grow at a CAGR of 10.34%, to USD 27.42 billion by 2030.

The scope of neuroscience as a market research domain encompasses the study and application of biological and cognitive sciences to understand and enhance human brain function. This field's necessity arises from growing demand for solutions to treat neurological disorders, mental health challenges, and degenerative diseases. Applications span pharmaceuticals, biotechnology, cognitive neuroscience, and neurotechnology, with end-use sectors including healthcare, education, and defense. Market growth is influenced by factors such as technological advancements in brain imaging, increased funding for neurological research, and a heightened focus on mental health awareness. The influx of artificial intelligence and machine learning technologies presents significant opportunities for innovation, such as personalized treatment plans and predictive analytics in mental health care. Furthermore, the expansion of telehealth services amid the COVID-19 pandemic has accelerated integration of neuroscience-driven applications in remote care settings. However, challenges persist, including high R&D costs, regulatory hurdles, and ethical considerations surrounding neurotechnological advancements. Additionally, the market is fragmented, with a few dominant players and numerous niche developers, adding competitive pressure. Areas ripe for innovation include developing non-invasive neurostimulation techniques, enhancing brain-computer interface technologies, and exploring the therapeutic potential of psychedelic substances and their neural impact. Business growth can be further bolstered by leveraging collaborations with universities and research institutions, fostering interdisciplinary research, and prioritizing patient-centric approaches in product development. As the market is inherently dynamic and rapidly evolving, staying ahead requires companies to remain vigilant of emerging trends and regulatory changes. The nature of the neuroscience market is therefore characterized by high innovation potential, tempered by challenges in monetization and ethical deployment, necessitating a strategic blend of research focus and market agility.

KEY MARKET STATISTICS
Base Year [2023] USD 13.77 billion
Estimated Year [2024] USD 15.11 billion
Forecast Year [2030] USD 27.42 billion
CAGR (%) 10.34%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Neuroscience Market

The Neuroscience Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of neurological disorders worldwide
    • Rise in drug discovery and development for neurological conditions
    • Increasing use of neuroscience to enhance brain health and cognitive functions
  • Market Restraints
    • High cost associated with neuroscience research
  • Market Opportunities
    • Emerging use of neuroscience in the development of personalized medicine
    • Favorable funding landscape for neuroscience research
  • Market Challenges
    • Functional limitations pertaining to the use of neurotechnologies

Porter's Five Forces: A Strategic Tool for Navigating the Neuroscience Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Neuroscience Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Neuroscience Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Neuroscience Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Neuroscience Market

A detailed market share analysis in the Neuroscience Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Neuroscience Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Neuroscience Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Neuroscience Market

A strategic analysis of the Neuroscience Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Neuroscience Market, highlighting leading vendors and their innovative profiles. These include Agilent Technologies, Inc., Bayer AG, Bio-Rad Laboratories, Inc., Brain Products GmbH, Compumedics Limited, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Gilson, Inc., GL Sciences Inc., Hitachi, Ltd., Illumina, Inc., JASCO Corporation, Merck KGaA, Metrohm AG, Natus Medical Incorporated, Novasep Holding SAS, PerkinElmer Inc., Pfizer Inc., Promega Corporation, QIAGEN GmbH, Restek Corporation, Shimadzu Corporation, Siemens AG, Thermo Fisher Scientific Inc., Waters Corporation, and YMC Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Neuroscience Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Diagnostic Solution, Drug Therapy, and Non-drug Therapy. The Diagnostic Solution is further studied across Molecular and Non-molecular. The Molecular is further studied across Immunoassay, Instruments, Kits & Consumables, Liquid Chromatography, PCR, Sequencing, and Software. The Non-molecular is further studied across Brainstem auditory evoked potential, Electroencephalography, and Imaging. The Drug Therapy is further studied across Neurological disorders and Neuropsychiatric disorders. The Neurological disorders is further studied across Alzheimer's disease, Epilepsy, Huntington's disease, Multiple sclerosis, Parkinson's disease, and Vascular dementia. The Neuropsychiatric disorders is further studied across Anxiety, Attention deficit, Autism spectrum, Insomnia, Mood disorder, and Substance abuse. The Non-drug Therapy is further studied across Behavioral Therapy and Digital Health Services. The Behavioral Therapy is further studied across Animal-assisted, Home-based, Inpatient, and Outpatient.
  • Based on End-User, market is studied across Diagnostic Laboratories, Hospitals, and Research & Academic Institutes.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of neurological disorders worldwide
      • 5.1.1.2. Rise in drug discovery and development for neurological conditions
      • 5.1.1.3. Increasing use of neuroscience to enhance brain health and cognitive functions
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with neuroscience research
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging use of neuroscience in the development of personalized medicine
      • 5.1.3.2. Favorable funding landscape for neuroscience research
    • 5.1.4. Challenges
      • 5.1.4.1. Functional limitations pertaining to the use of neurotechnologies
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Neuroscience Market, by Type

  • 6.1. Introduction
  • 6.2. Diagnostic Solution
    • 6.2.1. Molecular
      • 6.2.1.1. Immunoassay
      • 6.2.1.2. Instruments
      • 6.2.1.3. Kits & Consumables
      • 6.2.1.4. Liquid Chromatography
      • 6.2.1.5. PCR
      • 6.2.1.6. Sequencing
      • 6.2.1.7. Software
    • 6.2.2. Non-molecular
      • 6.2.2.1. Brainstem auditory evoked potential
      • 6.2.2.2. Electroencephalography
      • 6.2.2.3. Imaging
  • 6.3. Drug Therapy
    • 6.3.1. Neurological disorders
      • 6.3.1.1. Alzheimer's disease
      • 6.3.1.2. Epilepsy
      • 6.3.1.3. Huntington's disease
      • 6.3.1.4. Multiple sclerosis
      • 6.3.1.5. Parkinson's disease
      • 6.3.1.6. Vascular dementia
    • 6.3.2. Neuropsychiatric disorders
      • 6.3.2.1. Anxiety
      • 6.3.2.2. Attention deficit
      • 6.3.2.3. Autism spectrum
      • 6.3.2.4. Insomnia
      • 6.3.2.5. Mood disorder
      • 6.3.2.6. Substance abuse
  • 6.4. Non-drug Therapy
    • 6.4.1. Behavioral Therapy
      • 6.4.1.1. Animal-assisted
      • 6.4.1.2. Home-based
      • 6.4.1.3. Inpatient
      • 6.4.1.4. Outpatient
    • 6.4.2. Digital Health Services

7. Neuroscience Market, by End-User

  • 7.1. Introduction
  • 7.2. Diagnostic Laboratories
  • 7.3. Hospitals
  • 7.4. Research & Academic Institutes

8. Americas Neuroscience Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Neuroscience Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Neuroscience Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Agilent Technologies, Inc.
  • 2. Bayer AG
  • 3. Bio-Rad Laboratories, Inc.
  • 4. Brain Products GmbH
  • 5. Compumedics Limited
  • 6. Eli Lilly and Company
  • 7. F. Hoffmann-La Roche Ltd.
  • 8. Gilson, Inc.
  • 9. GL Sciences Inc.
  • 10. Hitachi, Ltd.
  • 11. Illumina, Inc.
  • 12. JASCO Corporation
  • 13. Merck KGaA
  • 14. Metrohm AG
  • 15. Natus Medical Incorporated
  • 16. Novasep Holding SAS
  • 17. PerkinElmer Inc.
  • 18. Pfizer Inc.
  • 19. Promega Corporation
  • 20. QIAGEN GmbH
  • 21. Restek Corporation
  • 22. Shimadzu Corporation
  • 23. Siemens AG
  • 24. Thermo Fisher Scientific Inc.
  • 25. Waters Corporation
  • 26. YMC Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. NEUROSCIENCE MARKET RESEARCH PROCESS
  • FIGURE 2. NEUROSCIENCE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL NEUROSCIENCE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL NEUROSCIENCE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL NEUROSCIENCE MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL NEUROSCIENCE MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL NEUROSCIENCE MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL NEUROSCIENCE MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES NEUROSCIENCE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES NEUROSCIENCE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. NEUROSCIENCE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. NEUROSCIENCE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. NEUROSCIENCE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL NEUROSCIENCE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL NEUROSCIENCE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. NEUROSCIENCE MARKET DYNAMICS
  • TABLE 7. GLOBAL NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL NEUROSCIENCE MARKET SIZE, BY MOLECULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL NEUROSCIENCE MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL NEUROSCIENCE MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL NEUROSCIENCE MARKET SIZE, BY KITS & CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL NEUROSCIENCE MARKET SIZE, BY LIQUID CHROMATOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL NEUROSCIENCE MARKET SIZE, BY PCR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL NEUROSCIENCE MARKET SIZE, BY SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL NEUROSCIENCE MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL NEUROSCIENCE MARKET SIZE, BY BRAINSTEM AUDITORY EVOKED POTENTIAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL NEUROSCIENCE MARKET SIZE, BY ELECTROENCEPHALOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL NEUROSCIENCE MARKET SIZE, BY IMAGING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL NEUROSCIENCE MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL NEUROSCIENCE MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL NEUROSCIENCE MARKET SIZE, BY HUNTINGTON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL NEUROSCIENCE MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL NEUROSCIENCE MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL NEUROSCIENCE MARKET SIZE, BY VASCULAR DEMENTIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL NEUROSCIENCE MARKET SIZE, BY ANXIETY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL NEUROSCIENCE MARKET SIZE, BY ATTENTION DEFICIT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL NEUROSCIENCE MARKET SIZE, BY AUTISM SPECTRUM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL NEUROSCIENCE MARKET SIZE, BY INSOMNIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL NEUROSCIENCE MARKET SIZE, BY MOOD DISORDER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL NEUROSCIENCE MARKET SIZE, BY SUBSTANCE ABUSE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL NEUROSCIENCE MARKET SIZE, BY ANIMAL-ASSISTED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL NEUROSCIENCE MARKET SIZE, BY HOME-BASED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL NEUROSCIENCE MARKET SIZE, BY INPATIENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL NEUROSCIENCE MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL NEUROSCIENCE MARKET SIZE, BY DIGITAL HEALTH SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL NEUROSCIENCE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL NEUROSCIENCE MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 62. AMERICAS NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 63. AMERICAS NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 64. AMERICAS NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. AMERICAS NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 66. ARGENTINA NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. ARGENTINA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 68. ARGENTINA NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 69. ARGENTINA NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 72. ARGENTINA NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 73. ARGENTINA NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 74. ARGENTINA NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 75. ARGENTINA NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. BRAZIL NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. BRAZIL NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 78. BRAZIL NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 79. BRAZIL NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 80. BRAZIL NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 81. BRAZIL NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 82. BRAZIL NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 83. BRAZIL NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 84. BRAZIL NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 85. BRAZIL NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. CANADA NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. CANADA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 88. CANADA NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 89. CANADA NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 90. CANADA NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 91. CANADA NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 92. CANADA NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 93. CANADA NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 94. CANADA NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 95. CANADA NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. MEXICO NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. MEXICO NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 98. MEXICO NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 99. MEXICO NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 100. MEXICO NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 101. MEXICO NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 102. MEXICO NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 103. MEXICO NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 104. MEXICO NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 105. MEXICO NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. UNITED STATES NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. UNITED STATES NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 108. UNITED STATES NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 109. UNITED STATES NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 110. UNITED STATES NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 111. UNITED STATES NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 112. UNITED STATES NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 113. UNITED STATES NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 114. UNITED STATES NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 115. UNITED STATES NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. UNITED STATES NEUROSCIENCE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 128. AUSTRALIA NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. AUSTRALIA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 130. AUSTRALIA NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 131. AUSTRALIA NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 132. AUSTRALIA NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 133. AUSTRALIA NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 134. AUSTRALIA NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 135. AUSTRALIA NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 136. AUSTRALIA NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 137. AUSTRALIA NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. CHINA NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. CHINA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 140. CHINA NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 141. CHINA NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 142. CHINA NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 143. CHINA NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 144. CHINA NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 145. CHINA NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 146. CHINA NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 147. CHINA NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. INDIA NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. INDIA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 150. INDIA NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 151. INDIA NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 152. INDIA NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 153. INDIA NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 154. INDIA NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 155. INDIA NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 156. INDIA NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 157. INDIA NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. INDONESIA NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. INDONESIA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 160. INDONESIA NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 161. INDONESIA NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 162. INDONESIA NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 163. INDONESIA NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 164. INDONESIA NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 165. INDONESIA NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 166. INDONESIA NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 167. INDONESIA NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 168. JAPAN NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. JAPAN NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 170. JAPAN NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 171. JAPAN NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 172. JAPAN NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 173. JAPAN NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 174. JAPAN NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 175. JAPAN NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 176. JAPAN NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 177. JAPAN NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 178. MALAYSIA NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. MALAYSIA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 180. MALAYSIA NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 181. MALAYSIA NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 182. MALAYSIA NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 183. MALAYSIA NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 184. MALAYSIA NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 185. MALAYSIA NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 186. MALAYSIA NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 187. MALAYSIA NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 188. PHILIPPINES NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. PHILIPPINES NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 190. PHILIPPINES NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 191. PHILIPPINES NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 192. PHILIPPINES NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 193. PHILIPPINES NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 194. PHILIPPINES NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 195. PHILIPPINES NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 196. PHILIPPINES NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 197. PHILIPPINES NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 198. SINGAPORE NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. SINGAPORE NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 200. SINGAPORE NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 201. SINGAPORE NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 202. SINGAPORE NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 203. SINGAPORE NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 204. SINGAPORE NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 205. SINGAPORE NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 206. SINGAPORE NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 207. SINGAPORE NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH KOREA NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH KOREA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 210. SOUTH KOREA NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 211. SOUTH KOREA NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 212. SOUTH KOREA NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 213. SOUTH KOREA NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 214. SOUTH KOREA NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 215. SOUTH KOREA NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 216. SOUTH KOREA NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 217. SOUTH KOREA NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 218. TAIWAN NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. TAIWAN NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 220. TAIWAN NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 221. TAIWAN NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 222. TAIWAN NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 223. TAIWAN NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 224. TAIWAN NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 225. TAIWAN NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 226. TAIWAN NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 227. TAIWAN NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 228. THAILAND NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. THAILAND NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 230. THAILAND NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 231. THAILAND NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 232. THAILAND NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 233. THAILAND NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 234. THAILAND NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 235. THAILAND NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 236. THAILAND NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 237. THAILAND NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 238. VIETNAM NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 239. VIETNAM NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 240. VIETNAM NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 241. VIETNAM NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 242. VIETNAM NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 243. VIETNAM NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 244. VIETNAM NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 245. VIETNAM NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 246. VIETNAM NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 247. VIETNAM NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA NEUROSCIENCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 259. DENMARK NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 260. DENMARK NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 261. DENMARK NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 262. DENMARK NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 263. DENMARK NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 264. DENMARK NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 265. DENMARK NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 266. DENMARK NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 267. DENMARK NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 268. DENMARK NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 269. EGYPT NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 270. EGYPT NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 271. EGYPT NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 272. EGYPT NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 273. EGYPT NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 274. EGYPT NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 275. EGYPT NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 276. EGYPT NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 277. EGYPT NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 278. EGYPT NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 279. FINLAND NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 280. FINLAND NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 281. FINLAND NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 282. FINLAND NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 283. FINLAND NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 284. FINLAND NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 285. FINLAND NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 286. FINLAND NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 287. FINLAND NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 288. FINLAND NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 289. FRANCE NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 290. FRANCE NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 291. FRANCE NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 292. FRANCE NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 293. FRANCE NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 294. FRANCE NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 295. FRANCE NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 296. FRANCE NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 297. FRANCE NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 298. FRANCE NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 299. GERMANY NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 300. GERMANY NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 301. GERMANY NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 302. GERMANY NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 303. GERMANY NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 304. GERMANY NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 305. GERMANY NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 306. GERMANY NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 307. GERMANY NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 308. GERMANY NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 309. ISRAEL NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 310. ISRAEL NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 311. ISRAEL NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 312. ISRAEL NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 313. ISRAEL NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 314. ISRAEL NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 315. ISRAEL NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 316. ISRAEL NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 317. ISRAEL NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 318. ISRAEL NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 319. ITALY NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 320. ITALY NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 321. ITALY NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 322. ITALY NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 323. ITALY NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 324. ITALY NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 325. ITALY NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 326. ITALY NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 327. ITALY NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 328. ITALY NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 329. NETHERLANDS NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 330. NETHERLANDS NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 331. NETHERLANDS NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 332. NETHERLANDS NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 333. NETHERLANDS NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 334. NETHERLANDS NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 335. NETHERLANDS NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 336. NETHERLANDS NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 337. NETHERLANDS NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 338. NETHERLANDS NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 339. NIGERIA NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 340. NIGERIA NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 341. NIGERIA NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 342. NIGERIA NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 343. NIGERIA NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 344. NIGERIA NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 345. NIGERIA NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 346. NIGERIA NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 347. NIGERIA NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 348. NIGERIA NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 349. NORWAY NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 350. NORWAY NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 351. NORWAY NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 352. NORWAY NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 353. NORWAY NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 354. NORWAY NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 355. NORWAY NEUROSCIENCE MARKET SIZE, BY NEUROPSYCHIATRIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 356. NORWAY NEUROSCIENCE MARKET SIZE, BY NON-DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 357. NORWAY NEUROSCIENCE MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 358. NORWAY NEUROSCIENCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 359. POLAND NEUROSCIENCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 360. POLAND NEUROSCIENCE MARKET SIZE, BY DIAGNOSTIC SOLUTION, 2018-2030 (USD MILLION)
  • TABLE 361. POLAND NEUROSCIENCE MARKET SIZE, BY MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 362. POLAND NEUROSCIENCE MARKET SIZE, BY NON-MOLECULAR, 2018-2030 (USD MILLION)
  • TABLE 363. POLAND NEUROSCIENCE MARKET SIZE, BY DRUG THERAPY, 2018-2030 (USD MILLION)
  • TABLE 364. POLAND NEUROSCIENCE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2